Robert A. Johnson

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

P. Sabbatini, D. Hyman, J. Dupont, 2012, Investigational new drugs.

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

H. Linden, C. Hudis, N. Rosen, 2008 .

Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.

S. Lonial, P. Richardson, A. Chanan-Khan, 2007 .

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

A. Krishnan, S. Lonial, P. Richardson, 2006 .

Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones

T. Chou, S. Danishefsky, Rebecca M. Wilson, 2008, Proceedings of the National Academy of Sciences.

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

K. Anderson, A. Krishnan, S. Lonial, 2007 .

Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors

S. Otieno, A. Weir, S. Nasir, 2020, Case reports in hematology.